Celgene shaken again after the FDA kicks back their marketing application on blockbuster hopeful ozanimod
Celgene has been slammed with a refuse-to-file letter from the FDA for ozanimod, the biggest late-stage drug it has in the pipeline.
The biotech reported …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
